Loading institutional data...
Loading institutional data...
Held by 165 of 5,944 reporting institutions (90th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $2.66 today, the market must believe free cash flow compounds 30.2%/yr for a decade (off $5M normalized FCF).
The market's 30.2% is more optimistic than its 1-yr track record.
2-stage DCF · 0.19B shares · net debt -$20M
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
4/7 of the 9 checks — 2 couldn't be scored (see above), so the score is out of the 7 with data.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Needs granular two-year detail (receivables, PP&E, D&A, SG&A) — not fully reported.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Interest coverage is thin — monitor.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on $1M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Reinvestment has been productive — operating income grew well per dollar put in. Current ROIC on all capital: -24%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $20M covers all $13M of scheduled principal — no refinancing pressure. Scheduled principal only (excludes interest & revolver draws). As of 2014-09-30 (10-Q).
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest.
Cash vs short-term debt unavailable.
Short-term / long-term split not separately reported.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $233.8M 100.0% | $201.3M 100.0% | $186.8M 100.0% | $188.3M 100.0% | $159.5M 100.0% | $114.2M 100.0% | $93.8M 100.0% | $76.1M 100.0% | $51.3M 100.0% | $39.3M 100.0% |
| Cost of Revenue | — | — | — | — | — | $41.2M 36.0% | $33.4M 35.6% | $31.6M 41.6% | $22.5M 43.9% | $20.3M 51.7% |
| Cost of Products | — | — | — | — | — | — | — | — | $22.5M 43.9% | $20.3M 51.7% |
| Gross Profit | — | — | — | — | — | — | — | — | — | $16.9M 43.0% |
| Selling, General & Admin | $80.9M 34.6% | $75.9M 37.7% | $75.5M 40.4% | $83.3M 44.3% | $81.3M 51.0% | $67.0M 58.7% | $66.2M 70.6% | $56.8M 74.7% | $52.6M 102.5% | $49.0M 124.6% |
| Total Operating Expenses | $148.6M 63.6% | $134.8M 67.0% | $146.9M 78.6% | $147.4M 78.3% | $145.0M 90.9% | $131.4M 115.0% | $126.6M 135.0% | $99.4M 130.7% | $86.3M 168.2% | $80.4M 204.8% |
| Operating Income | -$8.7M -3.7% | -$14.2M -7.1% | -$30.1M -16.1% | -$34.1M -18.1% | -$48.9M -30.7% | -$58.3M -51.1% | -$66.2M -70.6% | -$55.0M -72.3% | -$57.5M -112.1% | -$61.4M -156.5% |
| Interest Expense | $8.3M 3.6% | $8.9M 4.4% | $8.4M 4.5% | $5.8M 3.1% | $4.9M 3.1% | $3.7M 3.3% | $6.1M 6.5% | $4.0M 5.3% | $3.0M 5.9% | $2.4M 6.2% |
| Other Income (Expense), net | -$6.6M -2.8% | -$6.5M -3.2% | -$7.3M -3.9% | -$8.3M -4.4% | -$5.1M -3.2% | -$1.2M -1.1% | -$4.8M -5.1% | -$2.3M -3.1% | $832K 1.6% | -$1.3M -3.3% |
| Pretax Income | -$15.3M -6.5% | -$20.8M -10.3% | -$37.3M -20.0% | -$42.3M -22.5% | -$54.1M -33.9% | -$59.6M -52.1% | -$71.0M -75.7% | -$57.3M -75.4% | -$56.7M -110.5% | -$62.7M -159.7% |
| Income Tax Expense | $354K 0.2% | $205K 0.1% | $325K 0.2% | $488K 0.3% | $319K 0.2% | $284K 0.2% | $263K 0.3% | $229K 0.3% | $3.9M 7.6% | $175K 0.4% |
| Net Income | -$15.6M -6.7% | -$20.9M -10.4% | -$37.5M -20.1% | -$42.8M -22.7% | -$54.4M -34.1% | -$59.9M -52.4% | -$71.2M -76.0% | -$57.6M -75.7% | -$60.6M -118.0% | -$62.9M -160.2% |
| Per Share | ||||||||||
| EPS (Basic) | $-0.08 | $-0.11 | $-0.21 | $-0.24 | $-0.32 | $-0.37 | — | $-0.44 | $-0.56 | $-0.62 |
| EPS (Diluted) | $-0.08 | $-0.11 | $-0.21 | $-0.24 | $-0.32 | $-0.37 | — | $-0.44 | $-0.56 | $-0.62 |
| Weighted Avg Shares (Basic) | 190.6M | 184.6M | 180.3M | 176.5M | 171.3M | 163.9M | 139.8M | 131.7M | 108.2M | 101.8M |
| Weighted Avg Shares (Diluted) | 190.6M | 184.6M | 180.3M | 176.5M | 171.3M | 163.9M | 139.8M | 131.7M | 108.2M | 101.8M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
EOD close · as of 2026-09-17
Where each multiple sits in its own 14-yr range · 28th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 41.6 | 35.6 | 36.0 | — | — | — | — | — |
| SG&A | 74.7 | 70.6 | 58.7 | 51.0 | 44.3 | 40.4 | 37.7 | 34.6 |
| Operating Income | -72.3 | -70.6 | -51.1 | -30.7 | -18.1 | -16.1 | -7.1 | -3.7 |
| Income Tax | 0.3 | 0.3 | 0.2 | 0.2 | 0.3 | 0.2 | 0.1 | 0.2 |
| Net Income | -75.7 | -76.0 | -52.4 | -34.1 | -22.7 | -20.1 | -10.4 | -6.7 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on CERS: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.02T | 49.6× | — | 15.7× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $643.4B | 24.2× | — | 6.8× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $362.6B | 19.9× | — | 5.6× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $340.0B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $244.5B | 36.5× | 31.5× | 5.5× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $156.1B | 20.2× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $130.4B | 33.5× | 28.6× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.5B | 24.8× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| LGVN | $117.4B | — | — | 97924.4× | -49.9% | 67.0% | -1894% | -400% | -400% | — | 31 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $108.8B | 33.9× | 18.7× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $103.4B | 23.1× | 16.3× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $81.0B | 18.7× | 19.4× | 5.7× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CERS | $511M | — | — | 2.2× | 16.1% | — | -6.7% | -24.3% | -24.3% | — | 165 |
Peers = companies sharing CERS's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.